Results of Ablatherm Focal HIFU study published in Prostate Cancer and Prostatic Diseases- EDAP

EDAP has announced the publication of long term results of Ablatherm Focal HIFU in the peer reviewed journal “Prostate Cancer and Prostatic Diseases.” This prospective study of HIFU hemiablation of prostate cancer was conducted by Professor Roland van Velthoven, Head of the Urology Department at Institut Bordet Oncology Center, Brussels, Belgium. With the initial patient treated in early 2007, it is the first prospective study of focal HIFU to enroll patients a follow-up extending to 8 years. The publication reports a 100% cancer specific survival at 5 years, a 94% rate of continence preservation and 80% rate of potency preservation.